Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies-Reference-Cited by-同舟云学术

Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies

Published:2010-06 Issue:3 Volume:10 Page:192-196
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Elstrom Rebecca L.,Martin Peter,Ostrow Katya,Barrientos Jacqueline,Chadburn Amy,Furman Richard,Ruan Jia,Shore Tsiporah,Schuster Michael,Cerchietti Leandro,Melnick Ari,Coleman Morton,Leonard John P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

5. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma;Philip;N Engl J Med,1987

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial;Blood Cancer Journal;2024-08-07

2. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome;Cancers;2024-06-07

3. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma;Medicine in Novel Technology and Devices;2024-06

4. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001;Blood;2024-02-01

5. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells;Cancer Research;2023-10-06